More
An internal survey of the FDA finds that two-thirds of the agency's scientists aren't confident the FDA can monitor drug safety.
The latest criticism of the agency could mean that federal regulators will ask drug companies to conduct more clinical trials of their medicines over a longer period of time and in a broader population of patients, reports Fortune magazine.
Such a move would likely result in increased pressure on drug prices, warn pharmaceutical companies, because drugs will have a shorter time in the marketplace before their patents run out.
With access to over one million professionals and more than 60 industry-specific publications,
